Trial Profile
Incidence of Opportunistic Infections in Rheumatoid Arthritis treated by Rituximab, Abatacept or Tocilizumab
Status:
Not stated
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Rituximab (Primary) ; Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results assessing the Incidence of Opportunistic Infections in Rheumatoid Arthritis treated by Rituximab, Abatacept or Tocilizumab, presented at the 19th Annual Congress of the European League Against Rheumatism